risk-assessment

To conduct a clinical trial EDC system risk assessment, define the system scope, identify potential failure modes, score them by Severity, Probability, and Detectability, calculate Risk Priority Numbers (RPNs), and develop mitigation strategies to ensure GxP compliance.

FMEA (Failure Mode and Effects Analysis) is a systematic method to identify, score, and prioritize risks. For clinical data integrity, it evaluates potential EDC system failures, calculates Risk Priority Numbers (RPNs), and classifies risks to define appropriate preventive, detective, and corrective controls.

To calculate RPNs for GxP compliance, score each identified EDC system failure mode across three dimensions: Severity, Probability, and Detectability. Multiplying these three scores yields the RPN, which is then used to classify the risk as Low, Medium, High, or Critical.

Yes, you can use this framework to assess new EDC data validation modules. It guides you to identify failure modes like incorrect edit check logic, score their impact on patient safety and data integrity, and define mitigation strategies such as enhanced testing protocols.

FMEA for clinical trial systems is highly structured but relies on accurate subjective scoring of Severity, Probability, and Detectability. The RPN calculation requires careful definition of scope and context to ensure risk acceptance decisions align with ICH guidelines and patient safety standards.

You need a formal risk assessment when introducing or modifying clinical trial EDC systems. It ensures patient safety, data integrity, and regulatory compliance by systematically identifying potential failure modes and documenting risk acceptance decisions with appropriate authority.